{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:56:21Z","timestamp":1792896981377,"version":"4.5.0"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.clim.2017.01.016","type":"journal-article","created":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T05:31:32Z","timestamp":1487655092000},"page":"8-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"special_numbering":"C","title":["Therapeutic antibody targeting of indoleamine-2,3-dioxygenase (IDO2) inhibits autoimmune arthritis"],"prefix":"10.1016","volume":"179","author":[{"given":"Lauren M.F.","family":"Merlo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Grabler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B.","family":"DuHadaway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Pigott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaylend","family":"Manley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George C.","family":"Prendergast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa D.","family":"Laury-Kleintop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Mandik-Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2017.01.016_bb0005","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/art.23177","article-title":"Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I","volume":"58","author":"Helmick","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2017.01.016_bb0010","first-page":"s128","article-title":"Epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis: a synopsis","volume":"20","author":"Gibofsky","year":"2014","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/j.clim.2017.01.016_bb0015","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.clinthera.2011.05.044","article-title":"Use of biologics in rheumatoid arthritis: current and emerging paradigms of care","volume":"33","author":"Curtis","year":"2011","journal-title":"Clin. Ther."},{"key":"10.1016\/j.clim.2017.01.016_bb0020","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","article-title":"2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis","volume":"64","author":"Singh","year":"2012","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.clim.2017.01.016_bb0025","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/08916934.2013.873413","article-title":"Therapeutic targets for rheumatoid arthritis: progress and promises","volume":"47","author":"Alghasham","year":"2014","journal-title":"Autoimmunity"},{"key":"10.1016\/j.clim.2017.01.016_bb0030","first-page":"168","article-title":"Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis","volume":"65","author":"Tian","year":"2007","journal-title":"Bull. NYU Hosp. Jt Dis."},{"key":"10.1016\/j.clim.2017.01.016_bb0035","first-page":"S95","article-title":"Side effects and management of side effects of methotrexate in rheumatoid arthritis","volume":"28","author":"Albrecht","year":"2010","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.clim.2017.01.016_bb0040","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/ard.2010.144998","article-title":"Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis","volume":"70","author":"Buch","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2017.01.016_bb0045","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2010.08076.x","article-title":"The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases","volume":"149","author":"Cooper","year":"2010","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.clim.2017.01.016_bb0050","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.semarthrit.2013.08.003","article-title":"Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs","volume":"43","author":"Solomon","year":"2014","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.clim.2017.01.016_bb0055","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1002\/acr.22281","article-title":"Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis","volume":"66","author":"Curtis","year":"2014","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.clim.2017.01.016_bb0060","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3109\/08916934.2014.914507","article-title":"1-Methyl-tryptophan synergizes with methotrexate to alleviate arthritis in a mouse model of arthritis","volume":"47","author":"Pigott","year":"2014","journal-title":"Autoimmunity"},{"key":"10.1016\/j.clim.2017.01.016_bb0065","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1002\/art.34406","article-title":"Addition of an indoleamine 2,3,-dioxygenase inhibitor to B cell-depletion therapy blocks autoreactive B cell activation and recurrence of arthritis in K\/BxN mice","volume":"64","author":"Pigott","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2017.01.016_bb0070","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2217\/imt.10.22","article-title":"Beyond immunosuppression: reconsidering indoleamine 2,3-dioxygenase as a pathogenic element of chronic inflammation","volume":"2","author":"Muller","year":"2010","journal-title":"Immunotherapy"},{"key":"10.1016\/j.clim.2017.01.016_bb0075","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.4049\/jimmunol.1303012","article-title":"IDO2 is a critical mediator of autoantibody production and inflammatory pathogenesis in a mouse model of autoimmune arthritis","volume":"192","author":"Merlo","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2017.01.016_bb0080","doi-asserted-by":"crossref","first-page":"4487","DOI":"10.4049\/jimmunol.1600141","article-title":"IDO2 modulates T cell-dependent autoimmune responses through a B cell-intrinsic mechanism","volume":"196","author":"Merlo","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2017.01.016_bb0085","doi-asserted-by":"crossref","first-page":"7509","DOI":"10.4049\/jimmunol.0804328","article-title":"The immunoregulatory enzyme IDO paradoxically drives B cell-mediated autoimmunity","volume":"182","author":"Scott","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2017.01.016_bb0090","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3389\/fimmu.2014.00585","article-title":"IDO2 in immunomodulation and autoimmune disease","volume":"5","author":"Prendergast","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2017.01.016_bb0095","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1096\/fasebj.5.11.1907934","article-title":"Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism","volume":"5","author":"Taylor","year":"1991","journal-title":"FASEB J."},{"key":"10.1016\/j.clim.2017.01.016_bb0100","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1126\/science.281.5380.1191","article-title":"Prevention of allogeneic fetal rejection by tryptophan catabolism","volume":"281","author":"Munn","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.clim.2017.01.016_bb0105","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/PSY.0b013e318266d0f5","article-title":"Indoleamine 2,3-dioxygenase activation and depressive symptoms: results from the Young Finns Study","volume":"74","author":"Elovainio","year":"2012","journal-title":"Psychosom. Med."},{"key":"10.1016\/j.clim.2017.01.016_bb0110","first-page":"56","article-title":"Tryptophan kynurenine metabolism as a common mediator of genetic and environmental impacts in major depressive disorder: the serotonin hypothesis revisited 40 years later","volume":"47","author":"Oxenkrug","year":"2010","journal-title":"Isr. J. Psychiatry Relat. Sci."},{"key":"10.1016\/j.clim.2017.01.016_bb0115","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1164\/rccm.201304-0700OC","article-title":"Endothelial indoleamine 2,3-dioxygenase protects against development of pulmonary hypertension","volume":"188","author":"Xiao","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.clim.2017.01.016_bb0120","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.2174\/092986711795656072","article-title":"Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases","volume":"18","author":"Prendergast","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.clim.2017.01.016_bb0125","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nrc1929","article-title":"Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors","volume":"6","author":"Muller","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.clim.2017.01.016_bb0130","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s10067-005-0056-6","article-title":"Tryptophan degradation increases with stage in patients with rheumatoid arthritis","volume":"25","author":"Schroecksnadel","year":"2006","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.clim.2017.01.016_bb0135","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2249.2007.03480.x","article-title":"Indoleamine 2,3-dioxygenase activity is increased in patients with systemic lupus erythematosus and predicts disease activation in the sunny season","volume":"150","author":"Pertovaara","year":"2007","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.clim.2017.01.016_bb0140","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/j.1365-2362.2011.02491.x","article-title":"Indoleamine 2,3-dioxygenase-expressing peripheral cells in rheumatoid arthritis and systemic lupus erythematosus: a cross-sectional study","volume":"41","author":"Furuzawa-Carballeda","year":"2011","journal-title":"Eur. J. Clin. Investig."},{"key":"10.1016\/j.clim.2017.01.016_bb0145","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1053\/j.gastro.2003.08.031","article-title":"Inhibition of indoleamine 2,3-dioxygenase augments trinitrobenzene sulfonic acid colitis in mice","volume":"125","author":"Gurtner","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clim.2017.01.016_bb0150","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0165-5728(02)00176-5","article-title":"Effect of indoleamine 2,3-dioxygenase on induction of experimental autoimmune encephalomyelitis","volume":"129","author":"Sakurai","year":"2002","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.clim.2017.01.016_bb0155","doi-asserted-by":"crossref","first-page":"R50","DOI":"10.1186\/ar2205","article-title":"Inhibition of indoleamine 2,3-dioxygenase-mediated tryptophan catabolism accelerates collagen-induced arthritis in mice","volume":"9","author":"Szanto","year":"2007","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.clim.2017.01.016_bb0160","doi-asserted-by":"crossref","first-page":"6303","DOI":"10.4049\/jimmunol.0901577","article-title":"IDO mediates TLR9-driven protection from experimental autoimmune diabetes","volume":"183","author":"Fallarino","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2017.01.016_bb0165","doi-asserted-by":"crossref","first-page":"6690","DOI":"10.1073\/pnas.0708809105","article-title":"Indoleamine 2,3-dioxygenase in lung dendritic cells promotes Th2 responses and allergic inflammation","volume":"105","author":"Xu","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.clim.2017.01.016_bb0170","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/j.1398-9995.2012.02830.x","article-title":"The indoleamine 2,3-dioxygenase (IDO) pathway controls allergy","volume":"67","author":"von Bubnoff","year":"2012","journal-title":"Allergy"},{"key":"10.1016\/j.clim.2017.01.016_bb0175","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/intimm\/dxt073","article-title":"IDO2 is critical for IDO1-mediated T cell regulation and exerts a non-redundant function in inflammation","volume":"26","author":"Metz","year":"2014","journal-title":"Int. Immunol."},{"key":"10.1016\/j.clim.2017.01.016_bb0180","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.4161\/onci.21716","article-title":"IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: a novel IDO effector pathway targeted by D-1-methyl-tryptophan","volume":"1","author":"Metz","year":"2012","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.clim.2017.01.016_bb0185","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1073\/pnas.1117736109","article-title":"Tolerance to apoptotic cells is regulated by indoleamine 2,3-dioxygenase","volume":"109","author":"Ravishankar","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.clim.2017.01.016_bb0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0150075","article-title":"IDO1 deficiency does not affect disease in mouse models of systemic juvenile idiopathic arthritis and secondary hemophagocytic lymphohistiocytosis","volume":"11","author":"Put","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.clim.2017.01.016_bb0195","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc1913","article-title":"Comparing antibody and small-molecule therapies for cancer","volume":"6","author":"Imai","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.clim.2017.01.016_bb0200","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1600-065X.2010.00945.x","article-title":"B-cell targeted therapies in human autoimmune diseases: an updated perspective","volume":"237","author":"Townsend","year":"2010","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.clim.2017.01.016_bb0205","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.semarthrit.2015.10.001","article-title":"Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis","volume":"45","author":"Cantini","year":"2016","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.clim.2017.01.016_bb0210","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nrrheum.2015.180","article-title":"Inflammation in rheumatology in 2015: new tools to tackle inflammatory arthritis","volume":"12","author":"Dinarello","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.clim.2017.01.016_bb0215","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1515\/folmed-2015-0025","article-title":"Monoclonal antibody drugs for systemic lupus erythematosus","volume":"57","author":"Kamenarska","year":"2015","journal-title":"Folia Med."},{"key":"10.1016\/j.clim.2017.01.016_bb0220","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.autrev.2016.03.006","article-title":"Therapeutic strategies targeting B-cells in multiple sclerosis","volume":"15","author":"Milo","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.clim.2017.01.016_bb0225","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s10637-016-0349-4","article-title":"CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies","volume":"34","author":"Safdari","year":"2016","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.clim.2017.01.016_bb0230","first-page":"13","article-title":"Translating basic mechanisms of IgG effector activity into next generation cancer therapies","volume":"12","author":"Nimmerjahn","year":"2012","journal-title":"Cancer Immun."},{"key":"10.1016\/j.clim.2017.01.016_bb0235","first-page":"1","article-title":"Programmed death-1 immune checkpoint blockade in the treatment of hematological malignancies","author":"Tsirigotis","year":"2016","journal-title":"Ann. Med."},{"key":"10.1016\/j.clim.2017.01.016_bb0240","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12916-016-0623-5","article-title":"Cancer immunotherapy: the beginning of the end of cancer?","volume":"14","author":"Farkona","year":"2016","journal-title":"BMC Med."},{"key":"10.1016\/j.clim.2017.01.016_bb0245","doi-asserted-by":"crossref","first-page":"99ra85","DOI":"10.1126\/scitranslmed.3002296","article-title":"Targeting intracellular oncoproteins with antibody therapy or vaccination","volume":"3","author":"Guo","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.clim.2017.01.016_bb0250","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1158\/0008-5472.CAN-14-2278","article-title":"Optimizing a lupus autoantibody for targeted cancer therapy","volume":"75","author":"Noble","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.clim.2017.01.016_bb0255","doi-asserted-by":"crossref","first-page":"176ra33","DOI":"10.1126\/scitranslmed.3005661","article-title":"Targeting the intracellular WT1 oncogene product with a therapeutic human antibody","volume":"5","author":"Dao","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.clim.2017.01.016_bb0260","doi-asserted-by":"crossref","first-page":"6494","DOI":"10.1158\/0008-5472.CAN-13-1110","article-title":"Antitumor efficacy of a monoclonal antibody that inhibits the activity of cancer-associated carbonic anhydrase XII","volume":"73","author":"Gondi","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.clim.2017.01.016_bb0265","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/nprot.2007.173","article-title":"Collagen-induced arthritis","volume":"2","author":"Brand","year":"2007","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.clim.2017.01.016_bb0270","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/nm1107","article-title":"4-1BB-mediated immunotherapy of rheumatoid arthritis","volume":"10","author":"Seo","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.clim.2017.01.016_bb0275","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/art.24446","article-title":"Indoleamine 2,3 dioxygenase-mediated tryptophan catabolism regulates accumulation of Th1\/Th17 cells in the joint in collagen-induced arthritis","volume":"60","author":"Criado","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2017.01.016_bb0280","doi-asserted-by":"crossref","first-page":"5393894","DOI":"10.1155\/2016\/5393894","article-title":"CD4+ T cell fate in glomerulonephritis: a tale of Th1, Th17, and novel Treg subtypes","volume":"2016","author":"Krebs","year":"2016","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.clim.2017.01.016_bb0285","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1600-065X.2008.00631.x","article-title":"The role of IL-21 in regulating B-cell function in health and disease","volume":"223","author":"Ettinger","year":"2008","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.clim.2017.01.016_bb0290","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.4049\/jimmunol.0804350","article-title":"A positive feedback loop of IL-21 signaling provoked by homeostatic CD4+CD25- T cell expansion is essential for the development of arthritis in autoimmune K\/BxN mice","volume":"182","author":"Jang","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2017.01.016_bb0295","first-page":"34","article-title":"Fcgamma receptors as regulators of immune responses","volume":"8","author":"Nimmerjahn","year":"2008","journal-title":"Nat. Rev."},{"key":"10.1016\/j.clim.2017.01.016_bb0300","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/0092-8674(94)90115-5","article-title":"FcR gamma chain deletion results in pleiotrophic effector cell defects","volume":"76","author":"Takai","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.clim.2017.01.016_bb0305","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1126\/science.1535455","article-title":"Cytoplasmic domain heterogeneity and functions of IgG Fc receptors in B lymphocytes","volume":"256","author":"Amigorena","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.clim.2017.01.016_bb0310","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/369340a0","article-title":"A 13-amino-acid motif in the cytoplasmic domain of Fc gamma RIIB modulates B-cell receptor signalling","volume":"369","author":"Muta","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.clim.2017.01.016_bb0315","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1002\/eji.201142302","article-title":"Development and characterisation of monoclonal antibodies specific for the murine inhibitory Fc gamma RIIB (CD32B)","volume":"42","author":"Williams","year":"2012","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.clim.2017.01.016_bb0320","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.2353\/ajpath.2010.100195","article-title":"Characterization of the KRN cell transfer model of rheumatoid arthritis (KRN-CTM), a chronic yet synchronized version of the K\/BxN mouse","volume":"177","author":"LaBranche","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.clim.2017.01.016_bb0325","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/PPO.0b013e3181eb3343","article-title":"Indoleamine 2,3-dioxygenase: is it an immune suppressor?","volume":"16","author":"Soliman","year":"2010","journal-title":"Cancer J."},{"key":"10.1016\/j.clim.2017.01.016_bb0330","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.3004","article-title":"Overcoming tumor antigen anergy in human malignancies using the novel indoleamine 2,3-dioxygenase (IDO) enzyme inhibitor, 1-methyl-D-tryptophan (1MT)","volume":"27","author":"Soliman","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clim.2017.01.016_bb0335","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.3069","article-title":"A phase I study of ad.p53 DC vaccine in combination with indoximod in metastatic solid tumors","author":"Soliman","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clim.2017.01.016_bb0340","doi-asserted-by":"crossref","first-page":"8136","DOI":"10.18632\/oncotarget.2357","article-title":"A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors","volume":"5","author":"Soliman","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.clim.2017.01.016_bb0345","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00726-010-0475-9","article-title":"Biochemical characteristics and inhibitor selectivity of mouse indoleamine 2,3-dioxygenase-2","volume":"39","author":"Austin","year":"2010","journal-title":"Amino Acids"},{"key":"10.1016\/j.clim.2017.01.016_bb0350","doi-asserted-by":"crossref","first-page":"7641","DOI":"10.1016\/j.bmcl.2012.10.010","article-title":"Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2","volume":"22","author":"Bakmiwewa","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.clim.2017.01.016_bb0355","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2174\/138920101506140910150612","article-title":"The use of biologic therapies in the treatment of rheumatoid arthritis","volume":"15","author":"Wang","year":"2014","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.clim.2017.01.016_bb0360","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2017.01.016_bb0365","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group","volume":"343","author":"Lipsky","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2017.01.016_bb0370","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2017.01.016_bb0375","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","article-title":"Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis","volume":"344","author":"Elliott","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2017.01.016_bb0380","doi-asserted-by":"crossref","first-page":"750","DOI":"10.4161\/cbt.7.5.5764","article-title":"Monoclonal antibodies target intracellular PRL phosphatases to inhibit cancer metastases in mice","volume":"7","author":"Guo","year":"2008","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.clim.2017.01.016_bb0385","doi-asserted-by":"crossref","first-page":"532","DOI":"10.4049\/jimmunol.0903624","article-title":"CD11c+ dendritic cells and B cells contribute to the tumoricidal activity of anti-DR5 antibody therapy in established tumors","volume":"185","author":"Haynes","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2017.01.016_bb0390","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1126\/science.1206954","article-title":"Inhibitory Fcgamma receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies","volume":"333","author":"Li","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.clim.2017.01.016_bb0395","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.4049\/jimmunol.1101135","article-title":"Interaction with FcgammaRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody","volume":"187","author":"White","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2017.01.016_bb0400","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1182\/blood-2011-01-330357","article-title":"Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy","volume":"118","author":"Lim","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clim.2017.01.016_bb0405","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.1182\/blood-2010-01-263533","article-title":"Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection","volume":"115","author":"Beers","year":"2010","journal-title":"Blood"}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661616306052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661616306052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T19:16:14Z","timestamp":1601666174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661616306052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":81,"alternative-id":["S1521661616306052"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2017.01.016","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic antibody targeting of indoleamine-2,3-dioxygenase (IDO2) inhibits autoimmune arthritis","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2017.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}